Every Form 4 that Inspiremd (NSPR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NSPR filings page.
InspireMD director Paul Stuka reported an open-market purchase of 20,000 shares of InspireMD, Inc. common stock on May 27, 2026 at $0.875 per share. Following this transaction, he directly holds 667,871 shares. Separately, 423,704 shares are held indirectly through Osiris Investment Partners, L.P., with no new transaction reported for those indirectly held shares.
InspireMD, Inc.’s Chief Commercial Officer Shane Thomas Gleason reported a series of open-market sales of common stock primarily to cover tax withholding on vested restricted stock. The latest transaction on May 19, 2026 involved selling 22,778 shares at a weighted average price of $1.01 per share.
The filing shows a total of 85,295 shares sold across 14 transactions since early 2025, all described as required sales under an automatic sales instruction letter effecting a sell-to-cover election. Following the most recent sale, Gleason directly holds 1,053,882 shares of InspireMD common stock.
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. He bought 10,000 shares on May 13, 2026 at $1.1575 per share and 5,000 shares on May 14, 2026 at $1.1500 per share, for a total of 15,000 shares.
After these direct purchases, he directly owned 647,871 shares. An additional 423,704 shares are held indirectly through Osiris Investment Partners, L.P.; the filing states no transaction occurred in those indirect holdings and that they are included for informational purposes, with beneficial ownership disclaimed except for any pecuniary interest.
InspireMD, Inc. CEO and President Marvin Slosman reported an open-market purchase of 21,000 shares of Common Stock at $1.20 per share. Following this transaction, he directly owns 3,556,658 InspireMD shares, indicating a modest increase in his personal stake in the company.
InspireMD, Inc. director Paul Stuka reported open-market purchases of 75,626 shares of Common Stock. He bought 65,626 shares on May 8, 2026 at a weighted average price between $1.15 and $1.16, and 10,000 shares on May 11, 2026 at a weighted average price between $1.17 and $1.20.
Following these purchases, he directly beneficially owned 632,871 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The amendment also corrects earlier reports by confirming certain shares were held directly rather than indirectly and states that these corrections did not change his pecuniary interest. It further clarifies that the transactions were not effected under a Rule 10b5-1(c) trading plan and that the Osiris-held shares are included here for informational purposes only.
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. On May 8, 2026, he bought 65,626 shares at a weighted average price of $1.16 per share, followed by another 10,000 shares on May 11, 2026 at a weighted average price of $1.19 per share.
After these transactions, Stuka directly beneficially owned 632,871 shares of InspireMD common stock. Footnotes state that, immediately before these trades, he directly owned 557,245 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The Osiris-held shares are reported for informational purposes, with Stuka disclaiming beneficial ownership except to the extent of his pecuniary interest.
InspireMD, Inc. director Ward Scott R. reported open-market purchases of company common stock. He bought 15,995 shares on May 6 and 73,255 shares on May 7 at a weighted average price of $1.15 per share, with individual trade prices ranging from $1.13 to $1.15. Following these transactions, he directly holds 237,096 shares of InspireMD common stock.
InspireMD, Inc. director Paul Stuka increased his stake through open-market purchases of Common Stock. On May 7, 2026, he bought 6,378 shares at $1.15 per share, and on May 6, 2026 he bought 1,517 shares at $1.12 per share. After these transactions, he directly holds 531,599 shares of InspireMD common stock. A footnote explains that the May 7 price reflects a weighted average for multiple trades executed between $1.14 and $1.15 per share.
InspireMD, Inc. director Gary S. Roubin made an open-market purchase of 90,000 shares of Common Stock. He bought the shares at a weighted average price of $1.18 per share, through multiple trades between $1.15 and $1.20. Following this transaction, he directly owns 834,478 shares, increasing his personal stake in the company.
InspireMD director Paul Stuka reported an open-market purchase of 2,710 shares of InspireMD common stock. The transaction occurred on December 9, 2025 at a weighted average price of $1.81 per share, in multiple trades between $1.80 and $1.81. Following this purchase, Stuka directly owned 391,628 shares. The Form 4/A amends a prior filing solely to correct the number of shares shown in one column, with no other changes.
InspireMD Chief Commercial Officer Shane Thomas Gleason reported a series of automatic stock sales to cover taxes on vested restricted stock. Between mid-January and early February 2026, he sold multiple small blocks of InspireMD common stock under a pre-established sell-to-cover instruction.
The filing explains that these transactions were required to satisfy tax withholding obligations tied to restricted stock vesting and were executed pursuant to an automatic sales instruction letter adopted on November 25, 2024, rather than being discretionary trades. After the most recent sale, Gleason beneficially owned 1,139,177 shares of InspireMD common stock directly.
InspireMD, Inc. director Scott R. Ward reported an equity award of common stock. On January 14, 2026, he received 88,053 shares of common stock at a price of $0 per share, characterized as an acquisition. These shares are restricted stock that will vest on January 14, 2027, as long as he continues in service with the company through that date. Following this grant, he beneficially owns 147,846 shares of InspireMD common stock directly.
InspireMD, Inc. reported that Chief Operating Officer Andrea Tommasoli received an award of 226,695 shares of common stock on January 14, 2026. The shares were acquired at a price of $0 per share, indicating a grant of restricted stock rather than an open-market purchase. Following this grant, Tommasoli beneficially owned 954,389 shares of InspireMD common stock directly.
According to the footnote, these shares are restricted stock that vest in three equal annual installments, with one-third scheduled to vest on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to Tommasoli’s continued service with the company. This structure ties a portion of the executive’s compensation to ongoing employment and future share value.
InspireMD, Inc. director Paul Stuka reported a grant of 132,076 shares of common stock as restricted stock on January 14, 2026. The award was reported at a price of $0 per share and will vest on January 14, 2027, provided he continues to serve, bringing his directly held common shares to 523,704.
The filing also notes 444,195 shares of InspireMD common stock held indirectly through Osiris Investment Partners, L.P. Mr. Stuka is the managing member of the general partner of Osiris and may be deemed to beneficially own these securities, but he disclaims beneficial ownership except to the extent of his pecuniary interest. No transaction occurred with respect to these Osiris-held shares; they are reported for informational purposes.
InspireMD, Inc. reported an equity award to its CEO and President, Marvin Slosman, in the form of 1,114,792 restricted stock units granted on January 14, 2026 at a price of $0 per unit. After this grant, he beneficially owns 3,535,658 InspireMD shares. These restricted stock units vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. director receives restricted stock grant. Director Gary S. Roubin reported an award of 88,053 shares of InspireMD common stock on January 14, 2026. The shares were acquired at a stated price of $0 per share as a stock award, increasing his beneficial ownership to 744,478 common shares held directly. The 88,053 shares are restricted stock that will vest on January 14, 2027, provided he continues to serve through that one-year grant anniversary date.
InspireMD, Inc. reported an equity grant to its Chief Financial Officer. A Form 4 shows CFO Michael Lawless received an award of 226,695 shares of common stock on January 14, 2026 at a price of $0 per share, increasing his directly held stake to 691,695 shares.
The new shares are restricted stock that vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. reported that Chief Commercial Officer Shane Gleason received an award of 453,390 shares of common stock on January 14, 2026 at a price of $0 per share.
These shares are restricted stock that vest in three equal annual installments on January 14, 2027, January 14, 2028 and January 14, 2029, conditioned on his continued service. After this grant, he directly beneficially owns 1,200,371 shares of InspireMD common stock.
InspireMD, Inc. director Danny L. Dearen reported a stock award of 44,030 shares of common stock on January 14, 2026. The Form 4 shows the shares were acquired at a price of $0 per share as a grant of restricted stock.
According to the footnote, these 44,030 shares are restricted stock that will vest on January 14, 2027, the one-year grant anniversary date, subject to his continued service. Following this grant, Dearen beneficially owns 102,047 shares of InspireMD common stock in direct ownership.
InspireMD, Inc. director Raymond W. Cohen reported receiving 44,030 shares of common stock on January 14, 2026 as an award of restricted stock. The shares were granted at a reported price of $0 per share, indicating an equity compensation grant rather than an open‑market purchase.
According to the filing, these restricted shares are scheduled to vest on January 14, 2027, subject to his continued service. After this grant, Cohen beneficially owned 92,417 shares of InspireMD common stock in direct ownership.
InspireMD, Inc. director Michael Berman reported an equity grant of common stock. On January 14, 2026, he received 88,053 shares of restricted common stock at a price of $0 per share, increasing his directly held beneficial ownership to 352,586 common shares.
The filing explains that these 88,053 shares are restricted stock that will vest on January 14, 2027, as long as he continues in service through that date. It also lists an additional 244,994 common shares as indirectly held through the Michael Berman Revocable Trust, with no transaction in those trust-held securities; they are included for informational reporting only.
InspireMD, Inc. director Paul Stuka reported an insider transaction involving 5,073 shares of the company's common stock on 12/09/2025 at a weighted average price of $1.81, with trades executed between $1.80 and $1.81 per share.
After this activity, he reports beneficial ownership of 391,628 shares held directly. A further 444,195 shares are held by Osiris Investment Partners, L.P., where he serves in a managing capacity; he may be deemed to beneficially own these but expressly disclaims beneficial ownership except to the extent of his pecuniary interest, and states that no transaction occurred in those indirect holdings.
InspireMD (NSPR) director insider buy: A reporting person serving as a director purchased 13,431 shares of common stock on 11/12/2025 at $1.62 per share.
After the purchase, the filing shows 373,715 shares beneficially owned directly. It also lists 444,195 shares held indirectly through Osiris Investment Partners, L.P.; the filing states the reporting person may be deemed to beneficially own those only to the extent of any pecuniary interest and includes them for informational purposes.
The signature indicates the report was filed by an attorney-in-fact for the reporting person.
Director Gary S. Roubin received 48,000 restricted shares of InspireMD common stock on 10/07/2025. The shares were issued at $0 and will vest on 10/07/2026 subject to continued service, increasing his total beneficial ownership to 656,425 shares. The grant is recorded as restricted stock and the transaction was reported on a Form 4 filed by a single reporting person.
Thomas J. Kester reported transactions in InspireMD, Inc. (NSPR) on a Form 4 filed 09/17/2025. The filing shows a grant of 37,815 shares of common stock on 09/15/2025 for services rendered as a director, increasing his beneficial ownership to 458,573 shares. The report also discloses an option grant of 19,041 options with a $2.38 exercise price, exercisable 09/15/2025 and expiring 09/15/2027, covering 19,041 underlying common shares. The explanatory note states these equity awards were granted in 2025 prior to Mr. Kester's resignation as a director, effective 09/16/2025. The form is signed 09/17/2025.